What are ASCO/OH(CCO) recommendations for systemic treatment of stage IV non–small cell lung cancer (NSCLC) in patients with MET exon 14 skipping mutations?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

See the list below:

  • For second-line treatment in patients who have  MET abnormalities other than exon 14 skipping mutations or who received MET-targeted therapy in the first-line setting, standard treatment for NSCLC without driver mutations should be offered.
  • For second-line treatment in patients with an  MET exon 14 skipping mutation who previously received or were ineligible for first-line chemotherapy with or without immunotherapy (ie, if MET-targeted therapy was not given in the first-line setting), capmatinib or tepotinib may be offered.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!